- Poster presentation
- Open Access
Regional myocardial edema detected by T2 mapping is a feature of cardiotoxicity in breast cancer patients receiving sequential therapy with anthracyclines and trastuzumab
© Thavendiranathan et al.; licensee BioMed Central Ltd. 2014
- Published: 16 January 2014
- Late Gadolinium Enhancement
- Myocardial Edema
- Late Gadolinium Enhancement Imaging
Cardiotoxicity from cancer chemotherapy is an important cause of morbidity and mortality in breast cancer survivors. Left ventricular (LV) systolic dysfunction due to sequential use of anthracyclines and trastuzumab has been reported in up to 20-25% of patients. The pathophysiological changes associated with LV dysfunction have not been described non-invasively. We performed cardiac MRI (cardiac MR) with T2 mapping to assess whether myocardial edema is a feature of acute cardiotoxicity in women with breast cancer receiving sequential anthracyclines and trastuzumab.
We prospectively recruited women with HER2+ breast cancer scheduled to receive anthracyclines followed by trastuzumab (Grp A) and patients during therapy with anthracyclines and trastuzumab who were diagnosed with subclinical cardiac toxicity (Grp B) using multi-gated acquisition scans (MUGA) based on Cardiac Review and Evaluation Committee's criteria. All patients (July to Aug 2013) underwent cardiac MR imaging at 1.5 Tesla with conventional steady state free precession cine and late gadolinium enhancement (LGE) imaging with addition of quantitative T2 mapping using a T2-prepared single-shot SSFP technique. LV volumes and systolic function were quantified and segmental T2 values for all 16 myocardial segments were obtained from basal, mid, and apical short axis views. T2 values > 59 ms were considered abnormal based on previously published data. Mann-Whitney rank sum test was used for comparisons.
This preliminary analysis of a larger ongoing study demonstrates significant increase in segmental T2 values in breast cancer patients with cardiotoxicity compared to those pre-initiation of chemotherapy. This suggests that myocardial edema may be a feature of cardiotoxicity that results from treatment with sequential anthracyclines and trastuzumab. Whether quantitative assessment of myocardial edema early during therapy can predict subsequent development of cardiotoxicity remains to be determined.
Grant Miller Cancer Research Fund.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.